nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—Gefitinib—Vandetanib—thyroid cancer	0.502	1	CrCrCtD
Lapatinib—EGFR—Vandetanib—thyroid cancer	0.231	0.781	CbGbCtD
Lapatinib—CYP3A5—Sorafenib—thyroid cancer	0.0127	0.0431	CbGbCtD
Lapatinib—CYP2C8—Sorafenib—thyroid cancer	0.0122	0.0414	CbGbCtD
Lapatinib—CYP2C19—Sorafenib—thyroid cancer	0.0103	0.0347	CbGbCtD
Lapatinib—ABCB1—Sorafenib—thyroid cancer	0.00829	0.028	CbGbCtD
Lapatinib—CYP3A4—Vandetanib—thyroid cancer	0.00824	0.0279	CbGbCtD
Lapatinib—ABCB1—Doxorubicin—thyroid cancer	0.00503	0.017	CbGbCtD
Lapatinib—CYP3A4—Sorafenib—thyroid cancer	0.00497	0.0168	CbGbCtD
Lapatinib—CYP3A4—Doxorubicin—thyroid cancer	0.00301	0.0102	CbGbCtD
Lapatinib—Left ventricular ejection fraction decreased—Epirubicin—thyroid cancer	0.00293	0.0364	CcSEcCtD
Lapatinib—Dermatitis acneiform—Vandetanib—thyroid cancer	0.00286	0.0356	CcSEcCtD
Lapatinib—Left ventricular ejection fraction decreased—Doxorubicin—thyroid cancer	0.00271	0.0336	CcSEcCtD
Lapatinib—TAP1—saliva-secreting gland—thyroid cancer	0.0027	0.0752	CbGeAlD
Lapatinib—PIK3C2B—saliva-secreting gland—thyroid cancer	0.00254	0.0706	CbGeAlD
Lapatinib—ERBB2—neck—thyroid cancer	0.00253	0.0704	CbGeAlD
Lapatinib—Peripheral sensory neuropathy—Sorafenib—thyroid cancer	0.00231	0.0287	CcSEcCtD
Lapatinib—Metastatic disease—Epirubicin—thyroid cancer	0.00212	0.0263	CcSEcCtD
Lapatinib—TAP1—trachea—thyroid cancer	0.00209	0.058	CbGeAlD
Lapatinib—ERBB2—saliva-secreting gland—thyroid cancer	0.00197	0.0549	CbGeAlD
Lapatinib—ERBB4—saliva-secreting gland—thyroid cancer	0.00197	0.0549	CbGeAlD
Lapatinib—PIK3C2B—trachea—thyroid cancer	0.00196	0.0544	CbGeAlD
Lapatinib—Metastatic disease—Doxorubicin—thyroid cancer	0.00196	0.0243	CcSEcCtD
Lapatinib—PI4KB—saliva-secreting gland—thyroid cancer	0.00185	0.0514	CbGeAlD
Lapatinib—Mucosal inflammation—Vandetanib—thyroid cancer	0.00177	0.022	CcSEcCtD
Lapatinib—TAP1—thyroid gland—thyroid cancer	0.00165	0.0459	CbGeAlD
Lapatinib—ERBB2—Afatinib—Vandetanib—thyroid cancer	0.00157	0.667	CbGdCrCtD
Lapatinib—PIK3C2B—thyroid gland—thyroid cancer	0.00155	0.0431	CbGeAlD
Lapatinib—Nail disorder—Vandetanib—thyroid cancer	0.00151	0.0187	CcSEcCtD
Lapatinib—Ejection fraction decreased—Epirubicin—thyroid cancer	0.00149	0.0185	CcSEcCtD
Lapatinib—PI4KB—trachea—thyroid cancer	0.00143	0.0396	CbGeAlD
Lapatinib—Haemoglobin decreased—Vandetanib—thyroid cancer	0.00142	0.0177	CcSEcCtD
Lapatinib—Interstitial lung disease—Vandetanib—thyroid cancer	0.00138	0.0172	CcSEcCtD
Lapatinib—Ejection fraction decreased—Doxorubicin—thyroid cancer	0.00137	0.0171	CcSEcCtD
Lapatinib—PIK3C2B—head—thyroid cancer	0.00137	0.0382	CbGeAlD
Lapatinib—Metastatic neoplasm—Epirubicin—thyroid cancer	0.00127	0.0158	CcSEcCtD
Lapatinib—ERBB2—thyroid gland—thyroid cancer	0.0012	0.0335	CbGeAlD
Lapatinib—ERBB4—thyroid gland—thyroid cancer	0.0012	0.0335	CbGeAlD
Lapatinib—Mucosal inflammation—Sorafenib—thyroid cancer	0.00119	0.0148	CcSEcCtD
Lapatinib—Metastatic neoplasm—Doxorubicin—thyroid cancer	0.00118	0.0146	CcSEcCtD
Lapatinib—PI4KB—thyroid gland—thyroid cancer	0.00113	0.0314	CbGeAlD
Lapatinib—ERBB2—head—thyroid cancer	0.00107	0.0297	CbGeAlD
Lapatinib—ERBB4—head—thyroid cancer	0.00107	0.0297	CbGeAlD
Lapatinib—Cardiotoxicity—Epirubicin—thyroid cancer	0.00104	0.0129	CcSEcCtD
Lapatinib—Blood bilirubin increased—Vandetanib—thyroid cancer	0.00103	0.0128	CcSEcCtD
Lapatinib—TAP1—lymph node—thyroid cancer	0.00102	0.0285	CbGeAlD
Lapatinib—EGFR—thyroid gland—thyroid cancer	0.00102	0.0284	CbGeAlD
Lapatinib—PI4KB—head—thyroid cancer	0.001	0.0278	CbGeAlD
Lapatinib—PIK3C2B—lymph node—thyroid cancer	0.000962	0.0267	CbGeAlD
Lapatinib—Haemoglobin decreased—Sorafenib—thyroid cancer	0.000959	0.0119	CcSEcCtD
Lapatinib—Cardiotoxicity—Doxorubicin—thyroid cancer	0.000958	0.0119	CcSEcCtD
Lapatinib—Interstitial lung disease—Sorafenib—thyroid cancer	0.000932	0.0116	CcSEcCtD
Lapatinib—Peripheral sensory neuropathy—Epirubicin—thyroid cancer	0.000853	0.0106	CcSEcCtD
Lapatinib—Peripheral sensory neuropathy—Doxorubicin—thyroid cancer	0.00079	0.00981	CcSEcCtD
Lapatinib—Neoplasm malignant—Sorafenib—thyroid cancer	0.000773	0.0096	CcSEcCtD
Lapatinib—ERBB2—lymph node—thyroid cancer	0.000748	0.0208	CbGeAlD
Lapatinib—Cardiac failure—Vandetanib—thyroid cancer	0.000728	0.00904	CcSEcCtD
Lapatinib—PI4KB—lymph node—thyroid cancer	0.000701	0.0195	CbGeAlD
Lapatinib—Blood bilirubin increased—Sorafenib—thyroid cancer	0.000698	0.00867	CcSEcCtD
Lapatinib—Dehydration—Vandetanib—thyroid cancer	0.00066	0.0082	CcSEcCtD
Lapatinib—Dry skin—Vandetanib—thyroid cancer	0.000651	0.00809	CcSEcCtD
Lapatinib—EGFR—lymph node—thyroid cancer	0.000634	0.0176	CbGeAlD
Lapatinib—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.000626	0.00778	CcSEcCtD
Lapatinib—Neutropenia—Vandetanib—thyroid cancer	0.000574	0.00713	CcSEcCtD
Lapatinib—Pneumonia—Vandetanib—thyroid cancer	0.00055	0.00684	CcSEcCtD
Lapatinib—Infestation NOS—Vandetanib—thyroid cancer	0.000547	0.0068	CcSEcCtD
Lapatinib—Infestation—Vandetanib—thyroid cancer	0.000547	0.0068	CcSEcCtD
Lapatinib—Stomatitis—Vandetanib—thyroid cancer	0.000533	0.00663	CcSEcCtD
Lapatinib—Renal failure acute—Sorafenib—thyroid cancer	0.000519	0.00645	CcSEcCtD
Lapatinib—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000518	0.00643	CcSEcCtD
Lapatinib—Epistaxis—Vandetanib—thyroid cancer	0.000516	0.00641	CcSEcCtD
Lapatinib—Cardiac failure—Sorafenib—thyroid cancer	0.000491	0.0061	CcSEcCtD
Lapatinib—Pain in extremity—Sorafenib—thyroid cancer	0.000479	0.00595	CcSEcCtD
Lapatinib—Cardiac disorder—Vandetanib—thyroid cancer	0.000456	0.00566	CcSEcCtD
Lapatinib—Angiopathy—Vandetanib—thyroid cancer	0.000446	0.00554	CcSEcCtD
Lapatinib—Dehydration—Sorafenib—thyroid cancer	0.000445	0.00553	CcSEcCtD
Lapatinib—Mediastinal disorder—Vandetanib—thyroid cancer	0.000443	0.0055	CcSEcCtD
Lapatinib—Mucosal inflammation—Epirubicin—thyroid cancer	0.00044	0.00547	CcSEcCtD
Lapatinib—Dry skin—Sorafenib—thyroid cancer	0.000439	0.00545	CcSEcCtD
Lapatinib—Alopecia—Vandetanib—thyroid cancer	0.000434	0.00539	CcSEcCtD
Lapatinib—Mental disorder—Vandetanib—thyroid cancer	0.00043	0.00535	CcSEcCtD
Lapatinib—Malnutrition—Vandetanib—thyroid cancer	0.000428	0.00531	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000422	0.00525	CcSEcCtD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—thyroid cancer	0.000408	0.173	CbGdCrCtD
Lapatinib—Mucosal inflammation—Doxorubicin—thyroid cancer	0.000408	0.00506	CcSEcCtD
Lapatinib—Neutropenia—Sorafenib—thyroid cancer	0.000387	0.00481	CcSEcCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—thyroid cancer	0.000377	0.16	CbGdCrCtD
Lapatinib—Nail disorder—Epirubicin—thyroid cancer	0.000376	0.00467	CcSEcCtD
Lapatinib—Cough—Vandetanib—thyroid cancer	0.000373	0.00464	CcSEcCtD
Lapatinib—Pneumonia—Sorafenib—thyroid cancer	0.000371	0.00461	CcSEcCtD
Lapatinib—Infestation NOS—Sorafenib—thyroid cancer	0.000369	0.00459	CcSEcCtD
Lapatinib—Infestation—Sorafenib—thyroid cancer	0.000369	0.00459	CcSEcCtD
Lapatinib—Arthralgia—Vandetanib—thyroid cancer	0.000364	0.00452	CcSEcCtD
Lapatinib—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000362	0.0045	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000362	0.00449	CcSEcCtD
Lapatinib—Stomatitis—Sorafenib—thyroid cancer	0.00036	0.00447	CcSEcCtD
Lapatinib—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000349	0.00434	CcSEcCtD
Lapatinib—Epistaxis—Sorafenib—thyroid cancer	0.000348	0.00433	CcSEcCtD
Lapatinib—Nail disorder—Doxorubicin—thyroid cancer	0.000348	0.00432	CcSEcCtD
Lapatinib—Infection—Vandetanib—thyroid cancer	0.000347	0.00431	CcSEcCtD
Lapatinib—Nervous system disorder—Vandetanib—thyroid cancer	0.000342	0.00425	CcSEcCtD
Lapatinib—Skin disorder—Vandetanib—thyroid cancer	0.000339	0.00421	CcSEcCtD
Lapatinib—Connective tissue disorder—Sorafenib—thyroid cancer	0.000326	0.00405	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000318	0.00395	CcSEcCtD
Lapatinib—Insomnia—Vandetanib—thyroid cancer	0.000316	0.00392	CcSEcCtD
Lapatinib—Dyspnoea—Vandetanib—thyroid cancer	0.000311	0.00387	CcSEcCtD
Lapatinib—Cardiac disorder—Sorafenib—thyroid cancer	0.000308	0.00382	CcSEcCtD
Lapatinib—Dyspepsia—Vandetanib—thyroid cancer	0.000307	0.00382	CcSEcCtD
Lapatinib—Decreased appetite—Vandetanib—thyroid cancer	0.000303	0.00377	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000301	0.00374	CcSEcCtD
Lapatinib—Fatigue—Vandetanib—thyroid cancer	0.000301	0.00374	CcSEcCtD
Lapatinib—Angiopathy—Sorafenib—thyroid cancer	0.000301	0.00374	CcSEcCtD
Lapatinib—Immune system disorder—Sorafenib—thyroid cancer	0.000299	0.00372	CcSEcCtD
Lapatinib—Mediastinal disorder—Sorafenib—thyroid cancer	0.000299	0.00371	CcSEcCtD
Lapatinib—Constipation—Vandetanib—thyroid cancer	0.000298	0.00371	CcSEcCtD
Lapatinib—Alopecia—Sorafenib—thyroid cancer	0.000293	0.00364	CcSEcCtD
Lapatinib—Blood disorder—Epirubicin—thyroid cancer	0.000292	0.00363	CcSEcCtD
Lapatinib—Mental disorder—Sorafenib—thyroid cancer	0.00029	0.00361	CcSEcCtD
Lapatinib—Malnutrition—Sorafenib—thyroid cancer	0.000288	0.00358	CcSEcCtD
Lapatinib—Neoplasm malignant—Epirubicin—thyroid cancer	0.000286	0.00355	CcSEcCtD
Lapatinib—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000285	0.00355	CcSEcCtD
Lapatinib—Abdominal pain—Vandetanib—thyroid cancer	0.000276	0.00343	CcSEcCtD
Lapatinib—Blood disorder—Doxorubicin—thyroid cancer	0.00027	0.00336	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000268	0.00333	CcSEcCtD
Lapatinib—Anaemia—Sorafenib—thyroid cancer	0.000267	0.00331	CcSEcCtD
Lapatinib—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000264	0.00328	CcSEcCtD
Lapatinib—Leukopenia—Sorafenib—thyroid cancer	0.000258	0.00321	CcSEcCtD
Lapatinib—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000258	0.0032	CcSEcCtD
Lapatinib—Cough—Sorafenib—thyroid cancer	0.000252	0.00313	CcSEcCtD
Lapatinib—Asthenia—Vandetanib—thyroid cancer	0.00025	0.00311	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000248	0.00308	CcSEcCtD
Lapatinib—Pruritus—Vandetanib—thyroid cancer	0.000247	0.00307	CcSEcCtD
Lapatinib—Arthralgia—Sorafenib—thyroid cancer	0.000246	0.00305	CcSEcCtD
Lapatinib—Myalgia—Sorafenib—thyroid cancer	0.000246	0.00305	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000244	0.00303	CcSEcCtD
Lapatinib—Diarrhoea—Vandetanib—thyroid cancer	0.000239	0.00297	CcSEcCtD
Lapatinib—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000239	0.00296	CcSEcCtD
Lapatinib—Anaphylactic shock—Sorafenib—thyroid cancer	0.000235	0.00292	CcSEcCtD
Lapatinib—Infection—Sorafenib—thyroid cancer	0.000234	0.00291	CcSEcCtD
Lapatinib—Nervous system disorder—Sorafenib—thyroid cancer	0.000231	0.00287	CcSEcCtD
Lapatinib—Skin disorder—Sorafenib—thyroid cancer	0.000229	0.00284	CcSEcCtD
Lapatinib—Anorexia—Sorafenib—thyroid cancer	0.000224	0.00279	CcSEcCtD
Lapatinib—Vomiting—Vandetanib—thyroid cancer	0.000222	0.00276	CcSEcCtD
Lapatinib—Rash—Vandetanib—thyroid cancer	0.00022	0.00273	CcSEcCtD
Lapatinib—Dermatitis—Vandetanib—thyroid cancer	0.00022	0.00273	CcSEcCtD
Lapatinib—Headache—Vandetanib—thyroid cancer	0.000219	0.00272	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000215	0.00266	CcSEcCtD
Lapatinib—Dyspnoea—Sorafenib—thyroid cancer	0.00021	0.00261	CcSEcCtD
Lapatinib—Nausea—Vandetanib—thyroid cancer	0.000207	0.00258	CcSEcCtD
Lapatinib—Dyspepsia—Sorafenib—thyroid cancer	0.000207	0.00257	CcSEcCtD
Lapatinib—Decreased appetite—Sorafenib—thyroid cancer	0.000205	0.00254	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000203	0.00253	CcSEcCtD
Lapatinib—Fatigue—Sorafenib—thyroid cancer	0.000203	0.00252	CcSEcCtD
Lapatinib—Constipation—Sorafenib—thyroid cancer	0.000201	0.0025	CcSEcCtD
Lapatinib—ABCB1—trachea—thyroid cancer	0.000198	0.00552	CbGeAlD
Lapatinib—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000193	0.00239	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—thyroid cancer	0.000192	0.00238	CcSEcCtD
Lapatinib—Hot flush—Epirubicin—thyroid cancer	0.000189	0.00235	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—thyroid cancer	0.000188	0.00233	CcSEcCtD
Lapatinib—Abdominal pain—Sorafenib—thyroid cancer	0.000186	0.00231	CcSEcCtD
Lapatinib—Cardiac failure—Epirubicin—thyroid cancer	0.000181	0.00225	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—thyroid cancer	0.000177	0.0022	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—thyroid cancer	0.000177	0.0022	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—thyroid cancer	0.000175	0.00218	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—thyroid cancer	0.000174	0.00216	CcSEcCtD
Lapatinib—Hypersensitivity—Sorafenib—thyroid cancer	0.000173	0.00215	CcSEcCtD
Lapatinib—Asthenia—Sorafenib—thyroid cancer	0.000169	0.0021	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—thyroid cancer	0.000168	0.00209	CcSEcCtD
Lapatinib—Pruritus—Sorafenib—thyroid cancer	0.000167	0.00207	CcSEcCtD
Lapatinib—Dehydration—Epirubicin—thyroid cancer	0.000165	0.00205	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—thyroid cancer	0.000164	0.00203	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—thyroid cancer	0.000162	0.00202	CcSEcCtD
Lapatinib—Diarrhoea—Sorafenib—thyroid cancer	0.000161	0.002	CcSEcCtD
Lapatinib—ABCB1—thyroid gland—thyroid cancer	0.000157	0.00436	CbGeAlD
Lapatinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000156	0.00194	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—thyroid cancer	0.000152	0.00189	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—thyroid cancer	0.00015	0.00187	CcSEcCtD
Lapatinib—Vomiting—Sorafenib—thyroid cancer	0.00015	0.00186	CcSEcCtD
Lapatinib—Rash—Sorafenib—thyroid cancer	0.000148	0.00184	CcSEcCtD
Lapatinib—Dermatitis—Sorafenib—thyroid cancer	0.000148	0.00184	CcSEcCtD
Lapatinib—Headache—Sorafenib—thyroid cancer	0.000147	0.00183	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000144	0.00179	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—thyroid cancer	0.000143	0.00178	CcSEcCtD
Lapatinib—Nausea—Sorafenib—thyroid cancer	0.00014	0.00174	CcSEcCtD
Lapatinib—ABCB1—head—thyroid cancer	0.000139	0.00387	CbGeAlD
Lapatinib—Pneumonia—Epirubicin—thyroid cancer	0.000137	0.0017	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—thyroid cancer	0.000136	0.00169	CcSEcCtD
Lapatinib—Infestation—Epirubicin—thyroid cancer	0.000136	0.00169	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000134	0.00166	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—thyroid cancer	0.000133	0.00165	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—thyroid cancer	0.000132	0.00164	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000129	0.0016	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—thyroid cancer	0.000129	0.0016	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—thyroid cancer	0.000127	0.00158	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—thyroid cancer	0.000126	0.00157	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—thyroid cancer	0.000126	0.00157	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000124	0.00154	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—thyroid cancer	0.000123	0.00153	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—thyroid cancer	0.00012	0.0015	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000119	0.00148	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—thyroid cancer	0.000119	0.00148	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—thyroid cancer	0.000114	0.00141	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000111	0.00138	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—thyroid cancer	0.000111	0.00138	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—thyroid cancer	0.000111	0.00137	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—thyroid cancer	0.00011	0.00137	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—thyroid cancer	0.000108	0.00134	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—thyroid cancer	0.000107	0.00133	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—thyroid cancer	0.000107	0.00132	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—thyroid cancer	0.000105	0.00131	CcSEcCtD
Lapatinib—Back pain—Epirubicin—thyroid cancer	0.000103	0.00128	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—thyroid cancer	0.000103	0.00128	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—thyroid cancer	0.000102	0.00127	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000102	0.00127	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—thyroid cancer	0.0001	0.00124	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—thyroid cancer	9.93e-05	0.00123	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—thyroid cancer	9.86e-05	0.00123	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—thyroid cancer	9.85e-05	0.00122	CcSEcCtD
Lapatinib—ABCB1—lymph node—thyroid cancer	9.75e-05	0.00271	CbGeAlD
Lapatinib—Leukopenia—Epirubicin—thyroid cancer	9.54e-05	0.00119	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—thyroid cancer	9.54e-05	0.00119	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—thyroid cancer	9.42e-05	0.00117	CcSEcCtD
Lapatinib—Cough—Epirubicin—thyroid cancer	9.3e-05	0.00116	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—thyroid cancer	9.12e-05	0.00113	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—thyroid cancer	9.08e-05	0.00113	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—thyroid cancer	9.08e-05	0.00113	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	9.01e-05	0.00112	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—thyroid cancer	8.83e-05	0.0011	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—thyroid cancer	8.72e-05	0.00108	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—thyroid cancer	8.7e-05	0.00108	CcSEcCtD
Lapatinib—Infection—Epirubicin—thyroid cancer	8.64e-05	0.00107	CcSEcCtD
Lapatinib—Cough—Doxorubicin—thyroid cancer	8.61e-05	0.00107	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—thyroid cancer	8.53e-05	0.00106	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—thyroid cancer	8.45e-05	0.00105	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—thyroid cancer	8.4e-05	0.00104	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—thyroid cancer	8.4e-05	0.00104	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	8.34e-05	0.00104	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—thyroid cancer	8.29e-05	0.00103	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—thyroid cancer	8.05e-05	0.001	CcSEcCtD
Lapatinib—Infection—Doxorubicin—thyroid cancer	8e-05	0.000994	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	7.93e-05	0.000985	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—thyroid cancer	7.9e-05	0.000981	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—thyroid cancer	7.87e-05	0.000978	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—thyroid cancer	7.82e-05	0.000971	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—thyroid cancer	7.76e-05	0.000964	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—thyroid cancer	7.67e-05	0.000953	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—thyroid cancer	7.66e-05	0.000951	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—thyroid cancer	7.56e-05	0.00094	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	7.51e-05	0.000933	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—thyroid cancer	7.5e-05	0.000932	CcSEcCtD
Lapatinib—Constipation—Epirubicin—thyroid cancer	7.44e-05	0.000924	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	7.34e-05	0.000911	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—thyroid cancer	7.28e-05	0.000905	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—thyroid cancer	7.18e-05	0.000892	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—thyroid cancer	7.12e-05	0.000884	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—thyroid cancer	7.09e-05	0.00088	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—thyroid cancer	7e-05	0.000869	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	6.95e-05	0.000863	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—thyroid cancer	6.94e-05	0.000862	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—thyroid cancer	6.88e-05	0.000855	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—thyroid cancer	6.88e-05	0.000854	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.58e-05	0.000818	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—thyroid cancer	6.41e-05	0.000796	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—thyroid cancer	6.36e-05	0.000791	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—thyroid cancer	6.24e-05	0.000776	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—thyroid cancer	6.16e-05	0.000765	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—thyroid cancer	5.95e-05	0.00074	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—thyroid cancer	5.93e-05	0.000737	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—thyroid cancer	5.78e-05	0.000718	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—thyroid cancer	5.7e-05	0.000708	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—thyroid cancer	5.53e-05	0.000687	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—thyroid cancer	5.51e-05	0.000684	CcSEcCtD
Lapatinib—Rash—Epirubicin—thyroid cancer	5.49e-05	0.000682	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—thyroid cancer	5.48e-05	0.000681	CcSEcCtD
Lapatinib—Headache—Epirubicin—thyroid cancer	5.45e-05	0.000677	CcSEcCtD
Lapatinib—Nausea—Epirubicin—thyroid cancer	5.17e-05	0.000642	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—thyroid cancer	5.12e-05	0.000636	CcSEcCtD
Lapatinib—Rash—Doxorubicin—thyroid cancer	5.08e-05	0.000631	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—thyroid cancer	5.07e-05	0.00063	CcSEcCtD
Lapatinib—Headache—Doxorubicin—thyroid cancer	5.04e-05	0.000627	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—thyroid cancer	4.78e-05	0.000594	CcSEcCtD
Lapatinib—ERBB4—Disease—HIF1A—thyroid cancer	1.67e-05	0.000199	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.65e-05	0.000197	CbGpPWpGaD
Lapatinib—EGFR—Disease—MEN1—thyroid cancer	1.65e-05	0.000197	CbGpPWpGaD
Lapatinib—TAP1—Immune System—AKT1—thyroid cancer	1.64e-05	0.000196	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CHST14—thyroid cancer	1.64e-05	0.000196	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—NRAS—thyroid cancer	1.64e-05	0.000196	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—thyroid cancer	1.63e-05	0.000194	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—KRAS—thyroid cancer	1.63e-05	0.000194	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—SST—thyroid cancer	1.62e-05	0.000193	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—NRAS—thyroid cancer	1.62e-05	0.000193	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—HRAS—thyroid cancer	1.61e-05	0.000192	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	1.6e-05	0.000191	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—HRAS—thyroid cancer	1.6e-05	0.000191	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CHST14—thyroid cancer	1.6e-05	0.000191	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—KRAS—thyroid cancer	1.6e-05	0.000191	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—HRAS—thyroid cancer	1.59e-05	0.000191	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—HRAS—thyroid cancer	1.59e-05	0.00019	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.58e-05	0.000189	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.58e-05	0.000189	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—AKT1—thyroid cancer	1.58e-05	0.000189	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—NRAS—thyroid cancer	1.58e-05	0.000188	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—thyroid cancer	1.56e-05	0.000187	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—PTEN—thyroid cancer	1.56e-05	0.000186	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.56e-05	0.000186	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CALCA—thyroid cancer	1.56e-05	0.000186	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	1.56e-05	0.000186	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—NRAS—thyroid cancer	1.55e-05	0.000185	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—AKT1—thyroid cancer	1.51e-05	0.000181	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	1.5e-05	0.00018	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	1.5e-05	0.000179	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	1.49e-05	0.000178	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—HRAS—thyroid cancer	1.49e-05	0.000178	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—HRAS—thyroid cancer	1.49e-05	0.000178	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—AKT1—thyroid cancer	1.49e-05	0.000178	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—HPGD—thyroid cancer	1.48e-05	0.000177	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—HRAS—thyroid cancer	1.48e-05	0.000177	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.47e-05	0.000176	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—PPARG—thyroid cancer	1.47e-05	0.000175	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—HRAS—thyroid cancer	1.47e-05	0.000175	CbGpPWpGaD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.47e-05	0.000175	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—HRAS—thyroid cancer	1.46e-05	0.000174	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—AKT1—thyroid cancer	1.42e-05	0.00017	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—AKT1—thyroid cancer	1.42e-05	0.000169	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	1.42e-05	0.000169	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—KRAS—thyroid cancer	1.41e-05	0.000169	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—HRAS—thyroid cancer	1.41e-05	0.000169	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—CDK1—thyroid cancer	1.41e-05	0.000168	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—AKT1—thyroid cancer	1.41e-05	0.000168	CbGpPWpGaD
Lapatinib—ERBB2—Disease—BRAF—thyroid cancer	1.4e-05	0.000168	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—AKT1—thyroid cancer	1.4e-05	0.000167	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—KRAS—thyroid cancer	1.39e-05	0.000166	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—NRAS—thyroid cancer	1.39e-05	0.000166	CbGpPWpGaD
Lapatinib—ERBB4—Disease—BRAF—thyroid cancer	1.38e-05	0.000165	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRG1—thyroid cancer	1.38e-05	0.000165	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—HRAS—thyroid cancer	1.38e-05	0.000165	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	1.38e-05	0.000165	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—AKT1—thyroid cancer	1.37e-05	0.000164	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRG1—thyroid cancer	1.36e-05	0.000163	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—HRAS—thyroid cancer	1.36e-05	0.000162	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—KRAS—thyroid cancer	1.36e-05	0.000162	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—KRAS—thyroid cancer	1.34e-05	0.00016	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—HPGD—thyroid cancer	1.32e-05	0.000158	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	1.32e-05	0.000158	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	1.32e-05	0.000158	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—AKT1—thyroid cancer	1.32e-05	0.000158	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—AKT1—thyroid cancer	1.32e-05	0.000158	CbGpPWpGaD
Lapatinib—EGFR—Disease—CALCA—thyroid cancer	1.31e-05	0.000157	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—AKT1—thyroid cancer	1.31e-05	0.000156	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—AKT1—thyroid cancer	1.3e-05	0.000155	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—HPGD—thyroid cancer	1.29e-05	0.000154	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—AKT1—thyroid cancer	1.29e-05	0.000154	CbGpPWpGaD
Lapatinib—EGFR—Immune System—CDK1—thyroid cancer	1.29e-05	0.000154	CbGpPWpGaD
Lapatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	1.28e-05	0.000153	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—NRAS—thyroid cancer	1.26e-05	0.00015	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.25e-05	0.000149	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—AKT1—thyroid cancer	1.25e-05	0.000149	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TERT—thyroid cancer	1.24e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.24e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IFNA2—thyroid cancer	1.24e-05	0.000148	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.23e-05	0.000148	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TSHR—thyroid cancer	1.23e-05	0.000147	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TERT—thyroid cancer	1.22e-05	0.000146	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—AKT1—thyroid cancer	1.22e-05	0.000146	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PRKAR1A—thyroid cancer	1.21e-05	0.000144	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.2e-05	0.000144	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—HRAS—thyroid cancer	1.2e-05	0.000143	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—AKT1—thyroid cancer	1.2e-05	0.000143	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—KRAS—thyroid cancer	1.2e-05	0.000143	CbGpPWpGaD
Lapatinib—EGFR—Disease—CDK1—thyroid cancer	1.19e-05	0.000142	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HIF1A—thyroid cancer	1.19e-05	0.000142	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.19e-05	0.000142	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—HRAS—thyroid cancer	1.18e-05	0.000141	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—AKT1—thyroid cancer	1.17e-05	0.00014	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HIF1A—thyroid cancer	1.17e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	1.17e-05	0.00014	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MEN1—thyroid cancer	1.16e-05	0.000138	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—HRAS—thyroid cancer	1.15e-05	0.000138	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—HRAS—thyroid cancer	1.14e-05	0.000136	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTGS2—thyroid cancer	1.13e-05	0.000135	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—AKT1—thyroid cancer	1.13e-05	0.000135	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.13e-05	0.000134	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTGS2—thyroid cancer	1.12e-05	0.000133	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.09e-05	0.00013	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—KRAS—thyroid cancer	1.08e-05	0.000129	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.07e-05	0.000128	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—PTEN—thyroid cancer	1.07e-05	0.000128	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—AKT1—thyroid cancer	1.06e-05	0.000127	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—PTEN—thyroid cancer	1.05e-05	0.000126	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.05e-05	0.000125	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTCH1—thyroid cancer	1.04e-05	0.000125	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—AKT1—thyroid cancer	1.04e-05	0.000125	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRG1—thyroid cancer	1.03e-05	0.000123	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—AKT1—thyroid cancer	1.02e-05	0.000122	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—HRAS—thyroid cancer	1.02e-05	0.000122	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—AKT1—thyroid cancer	1e-05	0.00012	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.96e-06	0.000119	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTEN—thyroid cancer	9.89e-06	0.000118	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—CHST14—thyroid cancer	9.87e-06	0.000118	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—BRAF—thyroid cancer	9.83e-06	0.000117	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—TPR—thyroid cancer	9.83e-06	0.000117	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTEN—thyroid cancer	9.74e-06	0.000116	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—BRAF—thyroid cancer	9.68e-06	0.000116	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	9.67e-06	0.000116	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SST—thyroid cancer	9.55e-06	0.000114	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—NRAS—thyroid cancer	9.55e-06	0.000114	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRG1—thyroid cancer	9.54e-06	0.000114	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—NRAS—thyroid cancer	9.41e-06	0.000112	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—HRAS—thyroid cancer	9.21e-06	0.00011	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CALCA—thyroid cancer	9.2e-06	0.00011	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—AKT1—thyroid cancer	8.98e-06	0.000107	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—NRAS—thyroid cancer	8.98e-06	0.000107	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—PTEN—thyroid cancer	8.89e-06	0.000106	CbGpPWpGaD
Lapatinib—ERBB2—Disease—NRAS—thyroid cancer	8.82e-06	0.000105	CbGpPWpGaD
Lapatinib—ERBB4—Disease—NRAS—thyroid cancer	8.69e-06	0.000104	CbGpPWpGaD
Lapatinib—EGFR—Disease—TERT—thyroid cancer	8.57e-06	0.000102	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—PTEN—thyroid cancer	8.54e-06	0.000102	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—TPR—thyroid cancer	8.51e-06	0.000102	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	8.37e-06	0.0001	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.34e-06	9.97e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CDK1—thyroid cancer	8.32e-06	9.95e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KRAS—thyroid cancer	8.22e-06	9.82e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HIF1A—thyroid cancer	8.19e-06	9.79e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KRAS—thyroid cancer	8.1e-06	9.68e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—HPGD—thyroid cancer	7.96e-06	9.51e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—NRAS—thyroid cancer	7.93e-06	9.47e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—KRAS—thyroid cancer	7.73e-06	9.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—NRAS—thyroid cancer	7.61e-06	9.1e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—TPR—thyroid cancer	7.6e-06	9.08e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KRAS—thyroid cancer	7.59e-06	9.07e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.59e-06	9.07e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KRAS—thyroid cancer	7.48e-06	8.94e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	7.48e-06	8.93e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—TPR—thyroid cancer	7.42e-06	8.86e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.41e-06	8.86e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—SLC5A5—thyroid cancer	7.36e-06	8.79e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	7.3e-06	8.72e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—CCND1—thyroid cancer	7.17e-06	8.57e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—CCND1—thyroid cancer	7.07e-06	8.44e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—HRAS—thyroid cancer	6.99e-06	8.35e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—PTEN—thyroid cancer	6.92e-06	8.27e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—HRAS—thyroid cancer	6.88e-06	8.23e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KRAS—thyroid cancer	6.83e-06	8.15e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—PTEN—thyroid cancer	6.82e-06	8.15e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—BRAF—thyroid cancer	6.79e-06	8.11e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.78e-06	8.1e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRG1—thyroid cancer	6.68e-06	7.98e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—HRAS—thyroid cancer	6.57e-06	7.85e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KRAS—thyroid cancer	6.55e-06	7.83e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—HRAS—thyroid cancer	6.45e-06	7.71e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	6.37e-06	7.61e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—HRAS—thyroid cancer	6.36e-06	7.59e-05	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.26e-06	7.48e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—RXRA—thyroid cancer	6.18e-06	7.39e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—NRAS—thyroid cancer	6.18e-06	7.38e-05	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—AKT1—thyroid cancer	6.17e-06	7.37e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—NRAS—thyroid cancer	6.08e-06	7.27e-05	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—AKT1—thyroid cancer	6.08e-06	7.26e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TERT—thyroid cancer	6e-06	7.17e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.97e-06	7.13e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—HRAS—thyroid cancer	5.8e-06	6.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—AKT1—thyroid cancer	5.8e-06	6.93e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HIF1A—thyroid cancer	5.74e-06	6.86e-05	CbGpPWpGaD
Lapatinib—ERBB2—Disease—AKT1—thyroid cancer	5.7e-06	6.81e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—SLC5A5—thyroid cancer	5.69e-06	6.8e-05	CbGpPWpGaD
Lapatinib—ERBB4—Disease—AKT1—thyroid cancer	5.61e-06	6.71e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—HRAS—thyroid cancer	5.57e-06	6.66e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	5.55e-06	6.63e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—thyroid cancer	5.48e-06	6.55e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—RXRA—thyroid cancer	5.35e-06	6.4e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.33e-06	6.37e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KRAS—thyroid cancer	5.32e-06	6.35e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KRAS—thyroid cancer	5.24e-06	6.26e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.21e-06	6.22e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—PTEN—thyroid cancer	5.18e-06	6.19e-05	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—AKT1—thyroid cancer	5.12e-06	6.12e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—NRAS—thyroid cancer	5.06e-06	6.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—AKT1—thyroid cancer	4.92e-06	5.88e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTEN—thyroid cancer	4.78e-06	5.71e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—RXRA—thyroid cancer	4.78e-06	5.71e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BRAF—thyroid cancer	4.75e-06	5.68e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—thyroid cancer	4.73e-06	5.65e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—RXRA—thyroid cancer	4.66e-06	5.57e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—thyroid cancer	4.65e-06	5.56e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.65e-06	5.55e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—NRAS—thyroid cancer	4.62e-06	5.52e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—TPR—thyroid cancer	4.57e-06	5.46e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—HRAS—thyroid cancer	4.52e-06	5.4e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.5e-06	5.37e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—HRAS—thyroid cancer	4.45e-06	5.32e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—KRAS—thyroid cancer	4.35e-06	5.2e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—NRAS—thyroid cancer	4.26e-06	5.1e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—AKT1—thyroid cancer	3.99e-06	4.77e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KRAS—thyroid cancer	3.98e-06	4.75e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—AKT1—thyroid cancer	3.93e-06	4.7e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PPARG—thyroid cancer	3.9e-06	4.66e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—HRAS—thyroid cancer	3.7e-06	4.42e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—KRAS—thyroid cancer	3.67e-06	4.39e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—CCND1—thyroid cancer	3.47e-06	4.14e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.42e-06	4.09e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PPARG—thyroid cancer	3.38e-06	4.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—HRAS—thyroid cancer	3.38e-06	4.04e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—PTEN—thyroid cancer	3.35e-06	4e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—AKT1—thyroid cancer	3.27e-06	3.9e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—HRAS—thyroid cancer	3.12e-06	3.73e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	3.07e-06	3.67e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PPARG—thyroid cancer	3.02e-06	3.61e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—NRAS—thyroid cancer	2.99e-06	3.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Immune System—AKT1—thyroid cancer	2.98e-06	3.56e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PPARG—thyroid cancer	2.95e-06	3.52e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—RXRA—thyroid cancer	2.87e-06	3.43e-05	CbGpPWpGaD
Lapatinib—EGFR—Disease—AKT1—thyroid cancer	2.75e-06	3.29e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTEN—thyroid cancer	2.68e-06	3.2e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—thyroid cancer	2.66e-06	3.18e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KRAS—thyroid cancer	2.57e-06	3.07e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—thyroid cancer	2.37e-06	2.84e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTEN—thyroid cancer	2.32e-06	2.77e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—thyroid cancer	2.32e-06	2.77e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—thyroid cancer	2.28e-06	2.73e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—HRAS—thyroid cancer	2.18e-06	2.61e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTEN—thyroid cancer	2.07e-06	2.47e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTEN—thyroid cancer	2.02e-06	2.41e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—AKT1—thyroid cancer	1.93e-06	2.3e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PPARG—thyroid cancer	1.81e-06	2.17e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—AKT1—thyroid cancer	1.54e-06	1.84e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.43e-06	1.71e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—AKT1—thyroid cancer	1.34e-06	1.6e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTEN—thyroid cancer	1.24e-06	1.49e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—AKT1—thyroid cancer	1.19e-06	1.43e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—AKT1—thyroid cancer	1.16e-06	1.39e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—AKT1—thyroid cancer	7.17e-07	8.57e-06	CbGpPWpGaD
